PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Australian Patent Office has granted Australian Patent No. AU2020212659, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This patent represents a significant milestone in the development and protection of PreveCeutical's proprietary technologies aimed at addressing unmet needs in pain management.The granted patent provides protection in Australia for novel cyclized peptides...
2025-12-04 7:00 AM EST
PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") and BioGene Therapeutics Inc. ("BioGene"), are pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025, October 20, 2025 and November 20, 2025, the previously announced plan of arrangement (the "Arrangement") involving the spin-off of 12,000,000...
2025-11-26 7:00 AM EST
PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 2025 will be issued new common shares of PreveCeutical and 0.02 of one share of BioGene Therapeutics Inc.About PreveCeuticalPreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical...
2025-11-20 12:26 PM EST
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025 and October 20, 2025, the Company announces that it will be completing its previously announced plan of arrangement (the "Arrangement") to be effected under Part 9, Division...
2025-11-20 7:00 AM EST
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche") of its previously announced $1,200,000 non-brokered private placement (the "Offering"), which Second Tranche consisted of...
2025-10-30 7:00 AM EDT
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025 and October 10, 2025, it will be proceeding to complete its previously announced plan of arrangement (the "Arrangement") to be effected under Part 9, Division 5 of the Business...
2025-10-20 7:00 AM EDT
PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that all resolutions presented at the Company's annual general and special meeting (the "Meeting") held on Friday, October 10, 2025, including the following:the election of Stephen Van Deventer, Makarand Jawadekar, Kathleen Rokita and C. Evan Ballantyne as directors of the Company; the ratification of the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the...
2025-10-10 4:00 PM EDT
PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its News Release of September 4, 2025, it has filed with the applicable Canadian securities regulatory authorities the management information circular dated September 9, 2025 and related meeting materials of the Company (the "Meeting Materials") for use at the annual general and special meeting (the "Meeting") of shareholders of PreveCeutical (the "PreveCeutical Shareholders") to be held...
2025-09-19 6:00 PM EDT
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated August 5, 2025, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 16,162,500 units (each, a "Unit") of the Company at a price of $0.04 per Unit for gross aggregate proceeds...
2025-09-05 4:58 PM EDT
PreveCeutical Announces Arrangement Agreement with BioGene Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") dated September 3, 2025 with its subsidiary, BioGene Therapeutics Inc. ("BioGene"), pursuant to which PreveCeutical intends to spin-out 12,000,000 common shares of BioGene (the "BioGene Spinout Shares") to the shareholders of PreveCeutical (the "PreveCeutical Shareholders") on a pro rata basis by way of a share capital reorganization...
2025-09-04 4:00 PM EDT
PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting and Director Resignation
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that, further to its News Release of June 25, 2025, July 8, 2025 and August 5, 2025, it has rescheduled its annual general and special meeting (the "Meeting") from September 29, 2025 to October 10, 2025 due to the necessity to comply with the various requirements in connection with the proposed plan of arrangement. At the Meeting, the...
2025-08-28 6:00 PM EDT
BioGene Therapeutics Inc. Appoints Dr. Francis Tavares, PhD., as Chief Technology Officer
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed of Dr. Francis Tavares as Chief Technology Officer effective on 19 August, 2025.Dr. Francis Tavares leads the biopharmaceutical industry, most recently serving as President, CEO, and Founder...
2025-08-20 7:00 AM EDT
BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Kamal Albarazanji as Senior Director of Metabolic Research effective on 18 August, 2025.Dr. Albarazanji brings a wealth of expertise in in vivo pharmacology, target validation, and...
2025-08-19 7:00 AM EDT
PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Release of June 25, 2025, it has rescheduled its annual general and special meeting from August 15, 2025 to September 5, 2025 at which the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve: the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne...
2025-07-09 7:00 AM EDT
PreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology Officer
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to have appointed Dr. Francis Tavares as a corporate advisor effective 27 June, 2025.Stephen Van Deventer, CEO of PreveCeutical, commented:"We are thrilled to welcome Dr. Francis Tavares to our executive team as our Chief Technology Officer. Francis's extraordinary career, spanning...
2025-06-30 11:53 AM EDT
PreveCeutical Announces Date for Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has scheduled its annual general and special meeting for August 15, 2025, at which the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve: the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne as directors of the Company; the ratification of the appointment...
2025-06-25 7:00 AM EDT
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 15,000,000 units in the capital of the Company (the "Units") at a price of $0.05 per Unit for gross proceeds of up to $750,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and one-half (1/2) of one Share purchase warrant (each...
2025-06-11 5:19 PM EDT
PreveCeutical Welcomes Dr. Deepak Sampath, PhD. as Corporate Advisor
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to have appointed Dr. Deepak Sampath as a corporate advisor effective 30 May, 2025.Stephen Van Deventer, CEO of PreveCeutical, commented:"We are thrilled to welcome Dr. Deepak Sampath to our Corporate Advisory Board. Deepak's extraordinary career, spanning over 25 years in...
2025-06-02 7:00 AM EDT
PreveCeutical Welcomes Stephen Glover as Corporate Advisor
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that Steve Glover has been appointed as Corporate Advisor effective on 24 May, 2025.Stephen Van Deventer, CEO of PreveCeutical, commented:"We are honoured to welcome Stephen Glover as our Corporate Advisor. Stephen's proven leadership in biopharma, combined with...
2025-05-26 7:00 AM EDT
PreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, following its news releases dated April 2, 2025, April 14, 2025, and April 28, 2025, it has successfully closed the final tranche ("Final Tranche") of its previously announced $700,000 non-brokered private placement ("Offering"). The Final Tranche comprised 5,279,400 units (each, a "Unit") of the Company at a price of $0.03 per Unit, resulting in gross...
2025-05-22 2:25 PM EDT